MedTrace Logo

Comparing MRI-Ultrasound Fusion and Cognitive-guided Biopsy for the Detection of csPCa: the PROFUSION Trial

NCT06303622 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1250

Last updated 2026-02-17

No results posted yet for this study

Summary

This study is an international multicentre RCT to compare the linically significant prostate cancer (csPCa) detection of cognitive-guided and MRI-USG guided biopsies in men with suspicious MRI lesion.

Conditions

Interventions

PROCEDURE

MRI-USG fusion approach

MRI-USG fusion approach prostate biopsy

PROCEDURE

Cognitive-guided approach

Cognitive-guided approach prostate biopsy

Sponsors & Collaborators

  • Nanjing Drum Tower Hospital, China

    collaborator UNKNOWN

  • China Medical University Hospital

    collaborator OTHER

  • Center of Postgraduate Medical Education, Poland

    collaborator UNKNOWN

  • Kaohsiung Medical University

    collaborator OTHER

  • Tuen Mun Hospital Hong Kong

    collaborator UNKNOWN

  • Queen Mary Hospital, Hong Kong

    collaborator OTHER

  • Stanford Cancer Institute

    collaborator UNKNOWN

  • Chinese University of Hong Kong

    lead OTHER

Principal Investigators

  • Peter Ka-Fungq CHIU · Chinese University of Hong Kong

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-01-08
Primary Completion
2026-12-31
Completion
2027-03-31

Countries

  • Hong Kong

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06303622 on ClinicalTrials.gov